NO942072L - Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks - Google Patents

Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks

Info

Publication number
NO942072L
NO942072L NO942072A NO942072A NO942072L NO 942072 L NO942072 L NO 942072L NO 942072 A NO942072 A NO 942072A NO 942072 A NO942072 A NO 942072A NO 942072 L NO942072 L NO 942072L
Authority
NO
Norway
Prior art keywords
growth factor
fibrosis
accumulation
extracellular matrix
inhibition
Prior art date
Application number
NO942072A
Other languages
English (en)
Norwegian (no)
Other versions
NO942072D0 (no
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Publication of NO942072D0 publication Critical patent/NO942072D0/no
Publication of NO942072L publication Critical patent/NO942072L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO942072A 1991-12-04 1994-06-03 Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks NO942072L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04
PCT/US1992/010550 WO1993010808A1 (fr) 1991-12-04 1992-12-04 INHIBITION DU FACTEUR DE CROISSANCE TRANSFORMATEUR β AFIN DE PREVENIR L'ACCUMULATION DE LA MATRICE EXTRACELLULAIRE

Publications (2)

Publication Number Publication Date
NO942072D0 NO942072D0 (no) 1994-06-03
NO942072L true NO942072L (no) 1994-08-03

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942072A NO942072L (no) 1991-12-04 1994-06-03 Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks

Country Status (10)

Country Link
EP (1) EP0616536B1 (fr)
JP (2) JP3854307B2 (fr)
AT (1) ATE177644T1 (fr)
AU (2) AU670770B2 (fr)
CA (1) CA2124591A1 (fr)
DE (1) DE69228700T2 (fr)
DK (1) DK0616536T3 (fr)
FI (1) FI942622A7 (fr)
NO (1) NO942072L (fr)
WO (1) WO1993010808A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
JPH09505057A (ja) * 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
WO1995026203A1 (fr) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Cicatrisation
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6316258B1 (en) * 1998-01-09 2001-11-13 University Of Utah Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGFβ using renin inhibitors
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
EP1423133B1 (fr) 2001-08-15 2009-01-14 Brown University Research Foundation Traitement de dystrophies musculaires et de troubles connexes
AU2003209308A1 (en) * 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
WO2004075917A1 (fr) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. Inhibiteur de fibrose d'organe ou de tissu
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
EP2862867A3 (fr) 2005-10-25 2015-08-05 The Johns Hopkins University Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP1983345A1 (fr) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Moyen et procédé pour l'évaluation du risque d'une intervention cardiaque chez des patients souffrant d'une maladie cardiaque coronarienne stable basés sur le GDF-15
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
CA2799735C (fr) 2010-05-17 2019-06-25 Brown University Mutants de biglycanes et produits therapeutiques associes et methodes d'utilisation
EP2659271A4 (fr) 2010-12-27 2015-04-08 Univ Brown Méthodes thérapeutiques et diagnostiques impliquant le biglycane et l'utrophine
CN103429732B (zh) 2010-12-27 2015-09-16 Lsip基金运营联合公司 iPS细胞及其制造方法
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
ES2897740T3 (es) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
CA2927898C (fr) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Medicament therapeutique pour des maladies associees a la mort cellulaire du reticulum endoplasmique dans l'endothelium de la cornee
WO2016187312A1 (fr) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour traiter une infection par alphavirus
WO2017223268A1 (fr) * 2016-06-22 2017-12-28 Yale University Compositions et procédés de resensibilisation de cellules à des inhibiteurs des protéines de bromodomaine et de domaine extraterminal (beti)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2019143219A1 (fr) * 2018-01-22 2019-07-25 고려대학교 산학협력단 Composition pharmaceutique pour la prévention ou le traitement du diabète, contenant du biglycane en tant que principe actif
FR3090320B1 (fr) * 2018-12-19 2023-03-03 Karim Bouzakri Utilisation de la decorine dans le traitement du diabete
WO2020209674A1 (fr) * 2019-04-11 2020-10-15 고려대학교 산학협력단 Composition pharmaceutique pour la prévention ou le traitement de l'obésité, contenant du biglycane en tant que principe actif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI921353A0 (fi) * 1989-09-29 1992-03-27 Jolla Cancer Res Found Inhibering av transformerande vaextfaktor b foer foerhindrande av ackumulation av extracellulaer matris.
WO1991010727A1 (fr) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibiteurs de facteurs regulateurs cellulaires

Also Published As

Publication number Publication date
DE69228700D1 (de) 1999-04-22
ATE177644T1 (de) 1999-04-15
DK0616536T3 (da) 1999-10-11
FI942622A7 (fi) 1994-07-27
EP0616536A1 (fr) 1994-09-28
JP2004043507A (ja) 2004-02-12
CA2124591A1 (fr) 1993-06-10
DE69228700T2 (de) 1999-09-09
AU670770B2 (en) 1996-08-01
FI942622A0 (fi) 1994-06-03
EP0616536B1 (fr) 1999-03-17
AU7051896A (en) 1997-01-16
WO1993010808A1 (fr) 1993-06-10
AU3242993A (en) 1993-06-28
JPH07504650A (ja) 1995-05-25
JP3854307B2 (ja) 2006-12-06
NO942072D0 (no) 1994-06-03

Similar Documents

Publication Publication Date Title
NO942072L (no) Inhibering av transformasjonsvekstfaktor e av akkumulering av ekstracellulær matriks
Oates et al. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials
Moss et al. Survival benefit with an implanted defibrillator in relation to mortality risk in chronic coronary heart disease
Sarter et al. What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction?
Vilayur et al. Emerging therapies for chronic kidney disease: what is their role?
Viazzi et al. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived
Samimi-Fard et al. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty
Togashi et al. Sudden cardiac arrest and syncope triggered by coronary spasm
Mehran et al. Angioplasty of complex lesions in ischemic rest angina: results of the Thrombolysis and Angioplasty in Unstable Angina (TAUSA) trial
Magne et al. Relation between renin-angiotensin system blockers and survival following isolated aortic valve replacement for aortic stenosis
Leibowitz Left ventricular hypertrophy and chronic renal insufficiency in the elderly
Payne et al. Blood vessel formation during tail regeneration in the leopard gecko (Eublepharis macularius): the blastema is not avascular
Letsas et al. Secondary prevention of sudden cardiac death in coronary artery spasm: is implantable cardioverter defibrillator always efficient?
Pai et al. Atrial fibrillation: new management strategies
Rosenbaum et al. Arrhythmias in patients with cardiac implantable electrical devices after implantation of a left ventricular assist device
Toso et al. Does antiarrhythmic drugs premedication improve electrical cardioversion success in persistent atrial fibrillation?
Sato et al. Recovery of electrophysiological parameters after conversion of atrial fibrillation
Vilvanathan et al. A randomized placebo-controlled trial with amiodarone for persistent atrial fibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty
Barone et al. Effect of acute CORticosteroids on conduction defects after Transcatheter Aortic Valve Implantation: the CORTAVI study
Kountouris et al. QRS dispersion: an electrocardiographic index of systolic left ventricular dysfunction in patients with left bundle branch block
Climent et al. Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation
Goldberg Mechanical factors and the electrocardiogram
Blessberger et al. Association of adipocytokines serum levels with left atrial thrombus formation in atrial fibrillation patients on oral anticoagulation (Alert)–A cross-sectional study
Biffi et al. Heart failure after myocardial revascularization: Risk markers
López-Cuenca et al. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in ‘high-risk’patients with ischemic heart disease